Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Lithium Hydroxide → 2-(6-chloro-benzothiazol-2-ylamino)-1-methyl-1H-benzimidazole-5-carboxylic acid
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Lithium Hydroxide | HCID 3939 | — |
| 반응물 | 2-(6-Chloro-benzothiazol-2-ylamino)-1-methyl-1H-benzoimidazole-5-carboxylic acid methyl ester | HCID 58397554 | — |
| 생성물 | 2-(6-chloro-benzothiazol-2-ylamino)-1-methyl-1H-benzimidazole-5-carboxylic acid | HCID 58397730 | 30.9% |
반응 단계
2-(6-Chloro-benzothiazol-2-ylamino)-1-methyl-1H-benzoimidazole-5-carboxylic acid (250 mg) was prepared by following General Procedure E starting from 2-(6-chloro-benzothiazol-2-ylamino)-1-methyl-1H-benzoimidazole-5-carboxylic acid methyl ester (842 mg) and lithium hydroxide (379 mg). LC/MS: m/z 359.9. 1H NMR (DMSO-d6, 400 MHz): δ 8.12 (s, 1H), 7.92 (d, 1H), 7.83 (d, 1H), 7.55 (s, 1H), 7.48 (d, 1H), 7.38 (dd, 1H), 3.65 (s, 3H), —COOH and —NH proton signal was not observed.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08759535B2 |
| 출처 데이터셋 | uspto-grants-2014_06 |
| ORD ID | ord-0389fe53502d42f89e8a327ca9133415 |
| 출처 메모 | uspto-grants-2014_06 |